| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
2,711.7420 | 1,341.2180 | 6,078.9530 | 4,031.1030 | 2,504.8960 |
|
Cost of Revenue
|
-2,282.6620 | -1,704.9670 | -2,562.8320 | -2,103.7070 | -1,722.1040 |
|
Gross Profit
|
429.0800 | -363.7490 | 3,516.1210 | 1,927.3960 | 782.7920 |
| Selling, General and Administrative Expenses
|
-4,220.4350 | -3,573.7440 | -3,937.8170 | -3,802.1030 | -3,444.7740 |
|
Research and Development Expenses
|
-1,246.0950 | -1,286.9320 | -927.0480 | -1,054.8950 | -1,021.8690 |
|
Operating Income/Expenses
|
-5,466.5300 | -4,860.6760 | -4,864.8650 | -4,856.9980 | -4,466.6430 |
|
Total Operating Profit/Loss
|
-5,037.4500 | -5,224.4250 | -1,348.7440 | -2,929.6020 | -3,683.8510 |
| Total Net Finance Income/Expense
|
-800.1620 | -184.8970 | 114.8520 | 220.0060 | -4.4950 |
|
Non-Operating Income/Expenses, Total
|
-800.1620 | -184.8970 | 114.8520 | 220.0060 | -4.4950 |
|
Pretax Income
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
|
Net Income from Continuing Operations
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
|
Net Income after Non-Controlling/Minority Interests
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
|
Net Income Available to Common Stockholders
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
|
Diluted Net Income Available to Common Stockholders
|
-5,837.6120 | -5,409.3220 | -1,233.8920 | -2,709.5960 | -3,688.3460 |
| Basic EPS
|
-0.66 | -0.67 | -0.16 | -0.34 | -0.49 |
| Diluted EPS
|
-0.66 | -0.67 | -0.16 | -0.34 | -0.49 |
|
Basic Weighted Average Shares Outstanding
|
8,826.7940 | 8,033.5010 | 7,894.9610 | 7,908.2660 | 7,528.0380 |
|
Diluted Weighted Average Shares Outstanding
|
8,826.7940 | 8,033.5010 | 7,894.9610 | 7,908.2660 | 7,528.0380 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-5,037.4500 | -5,224.4250 | -1,348.7440 | -2,929.6020 | -3,683.8510 |
|
EBITDA
|
-4,921.4940 | -5,108.0670 | -1,251.5310 | -2,868.9530 | -3,666.6400 |
|
Normalized EBITDA
|
-4,773.1830 | -4,941.4960 | -1,097.0810 | -2,742.1840 | -3,530.2900 |
|
Normalized Income
|
-5,689.3010 | -5,242.7510 | -1,079.4420 | -2,582.8270 | -3,551.9960 |
|
Total Unusual Items
|
148.3110 | 166.5710 | 154.4500 | 126.7690 | 136.3500 |
|
Total Unusual Items Excluding Goodwill
|
148.3110 | 166.5710 | 154.4500 | 126.7690 | 136.3500 |
|
Tax Effect of Unusual Items
|
0 | 0 | 0 | 0 | 0 |
|
Tax Rate, Calculated
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12/31/2022 - 2/2/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade